l e t t e r s previous melanoma GWAS. The observed effect size for the new locus was smaller than those observed for previously reported loci. Variants at the newly identified locus do not seem to be associated with human pigmentation or measures of nevus density, suggesting that they may influence melanoma risk through distinct mechanisms. Identification of the causal variants at this locus will help refine estimates of risk for this increasingly common cancer.
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We performed a genome-wide association study of melanoma in a discovery cohort of 2,168 Australian individuals with melanoma and 4,387 control individuals. In this discovery phase, we confirm several previously characterized melanoma-associated loci at MC1R, ASIP and MTAP-CDKN2A. We selected variants at nine loci for replication in three independent case-control studies (Europe: 2,804 subjects with melanoma, 7,618 control subjects; United States 1: 1,804 subjects with melanoma, 1,026 control subjects; United States 2: 585 subjects with melanoma, 6,500 control subjects). The combined meta-analysis of all case-control studies identified a new susceptibility locus at 1q21.3 (rs7412746, P = 9.0 × 10 −11 , OR in combined replication cohorts of 0.89 (95% CI 0.85-0.95)). We also show evidence suggesting that melanoma associates with 1q42.12 (rs3219090, P = 9.3 × 10 −8 ). The associated variants at the 1q21.3 locus span a region with ten genes, and plausible candidate genes for melanoma susceptibility include ARNT and SETDB1. Variants at the 1q21.3 locus do not seem to be associated with human pigmentation or measures of nevus density.
To date, genome-wide association studies (GWAS) for melanoma 1, 2 , pigmentation 3 and nevogenesis 4, 5 have identified a small number of low-penetrance melanoma susceptibility variants. These variants seem to affect melanoma risk through their involvement in the known melanoma-associated risk phenotypes of pigmentation and nevus count. In contrast to variants identified in other cancers, these variants have been shown to have relatively large effects on disease risk (odds ratios (OR) > 1.5); previous melanoma GWAS were underpowered to detect variants of small effect. Here we describe a large melanoma GWAS with sufficient power to detect the small effects typically observed for other cancers (1.1 < OR <1.5). Melanoma cases in individuals of European descent (N = 2,168) were selected from the Queensland study of Melanoma: Environment and Genetic Associations (Q-MEGA) 6 and the Australian Melanoma Family Study 7 (AMFS). Samples from Australian individuals of European descent from three different sources were used as controls (N = 4,387) [6] [7] [8] . Samples were genotyped on Illumina single-nucleotide polymorphism (SNP) arrays (samples from subjects with melanoma, Omni1-Quad or HumanHap610; control samples, Omni1-Quad, HumanHap610 or HumanHap670; Table 1 ). Samples from subjects with melanoma and control subjects were combined into a single data set for quality control (including principal component analysis for outlier removal) and imputation (Supplementary Note). Imputation based on data from the 1000 Genomes Project 9 allowed association testing for 5,480,804 well-imputed SNPs, which helped recover the full sample size for SNPs only typed on a subset of the arrays. After cleaning, the genomic inflation factor (λ) for those SNPs that were directly genotyped in all individuals in these discovery samples was 1.04 ( Supplementary Fig. 1) .
The results of the association tests for SNPs directly genotyped in all discovery samples are displayed in Figure 1 . (A similar pattern was seen for imputed SNPs; data not shown.) Three of the previously reported melanoma susceptibility loci (MC1R, ASIP and MTAP-CDKN2A) 1-4 reached genome-wide significance. Two additional noteworthy regions were identified at chromosome 1q42.12 and 1q21.3; for both loci, there was at least one SNP directly genotyped in all discovery samples with P < 1 × 10 −6 ( Table 2, Supplementary  Table 1 and Supplementary Fig. 2a,b) , as well as at least one imputed SNP with P < 5 × 10 −7 (Fig. 2a,b and Supplementary Fig. 3a,b) .
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For replication analyses, we selected nine of the new loci and evaluated them in silico using array data in two additional case-control studies from Europe 1 and the United States 10 ( Table 1 ). In each of the nine regions, we selected the most strongly associated SNPs present on both the Omni1-Quad and HumanHap610 arrays (as such SNPs were directly genotyped in all our samples, as well as in both sets of replication samples). We further limited follow-up region choice to regions with at least two SNPs with P < 10 −4 (that is, there had to be a supporting SNP in addition to the primary SNP). Both chromosome 1 regions showed significant association with melanoma in the replication samples, whereas the other seven regions did not ( Table 2 and Supplementary Figs. 4 and 5). We looked for further replication of the two chromosome 1 regions by examining an additional set of subjects with melanoma and control subjects from the United States ( Table 1 and Supplementary Table 2 ). In this analysis, rs7412746 clearly replicated (OR = 0.86, P = 0.0076, one-sided; meta-analysis of all three replication cohorts: OR = 0.89, 95% confidence interval (CI) 0.85-0.95, P = 1.5 × 10 −5 ), and rs3219090 showed a trend toward significance in the expected direction (OR = 0.95, P = 0.20, onesided; meta-analysis of all three replication cohorts: OR = 0.91, 95% CI 0.85-0.97, P = 3.4 × 10 −3 ). Based on the ORs seen in the replication cohorts, rs7412746 and rs3219090 each explain 0.1% of the genetic variance associated with melanoma risk. The meta-analysis P values for all the case-control studies combined were: P = 9.0 × 10 −11 for rs7412746 and P = 9.3 × 10 −8 (not meeting our genome-wide significance threshold of 5.0 × 10 −8 ) for rs3219090.
We tested for the association of rs7412746 and rs3219090 with pigmentation and nevus phenotypes, for which we had available data for a subset of our discovery sample (up to 1,146 individuals with melanoma and 1,080 control subjects, Supplementary Note). The rs7412746 SNP showed nominally significant association with blue versus non-blue eye color (P = 0.02), fair versus non-fair hair color (P = 0.01) and dark brown versus non-dark brown hair color (P = 0.02), as well as borderline association with nevus count (P = 0.06). The direction of the effect of rs7412746 on blue eye color, fair hair color, dark hair color and nevus count was the same in the subsets of individuals with melanoma and control individuals from our discovery sample. No association was seen between rs7412746 and skin color or freckling. The rs3219090 SNP was not associated with any pigmentation or nevus traits. Adjusting for pigmentation or nevus traits did not seem to change the association of either locus with melanoma (rs7412746: OR before correction 0.82 and after correction 0.84, P = 0.33 for difference; rs3219090: OR before correction 0.82 and after correction 0.83, P = 0.61 for difference).
We also tested for differences in the strength of the associations of the rs7412746 and rs3219090 SNPs with melanomas of early versus late onset (≤40 years of age compared with >40 years of age at onset) and with an in situ versus invasive phenotype (79% of cases were invasive) in the Australian cohort. We found no difference in the association ORs of these subsets. For early-onset versus controls, rs7412746 yielded OR = 0.83, 95% CI 0.75, 0.91 (P = 0.79 for difference in frequency between early and late), and rs3219090 yielded OR = 0.81, 95% CI 0.73, 0.90 (P = 0.63 for difference in frequency between early and late). For invasive versus controls, rs7412746 yielded OR = 0.80, 95% CI 0.73, 0.88 (P = 0.60 for difference in frequency between invasive and in situ), and rs3219090 yielded OR = 0.84, 95% CI 0.76, 0.93 (P = 0.38 for difference in frequency between invasive and in situ).
The ratio of males to females was similar in the groups of individuals with melanoma and in two of the control subject groups, but the third control subject group was all female (samples taken from an endometriosis study 8 ). We repeated our analysis without the allfemale sample set, and the results were similar: for rs7412746, OR = 0.82 in full data set, OR = 0.84 with the all-female control set removed (P = 0.42 for difference in frequency between endometriosis control set and remaining controls); for rs3219090, OR = 0.82 in full data set, OR = 0.82 with the all-female control set removed (P = 0.96 for difference in frequency between endometriosis control set and remaining controls). In the full Australian cohort, there were no differences in the strength of association with melanoma between groups of subjects with melanoma composed of only males or only females and control individuals: rs7412746, OR = 0.82 and rs3219090, OR = 0.81 in maleonly samples; rs7412746, OR = 0.84 and rs3219090, OR = 0.81 in female-only samples (P = 0.83, P = 0.90 for OR difference between sexes for rs7412746 and rs3219090, respectively).
The associated region at 149 Mb on chromosome 1 spans approximately 450 kb and encodes ten genes. The peak imputed SNP at this locus in samples from Australian case-control sample, rs267735 (P = 5.5 × 10 −8 ), maps to 1 kb upstream of the transcription start site (TSS) of LASS2 (genome build 36, position 149,215,120), although there is substantial linkage disequilibrium (LD) that spans several genes in the region. All but one (ANXA9) of these genes are expressed in normal cultured human melanocytes, and most are also expressed in the vast majority of the melanoma cell lines examined 11 . Several of the genes in the region have been implicated in cancer or cancerrelated processes, including MCL1 (encoding anti-apoptotic protein), ARNT (hypoxia-inducible factor 1-β) and LASS2 (ceramide sythase 2). The rs7412746 SNP significantly influences the expression (is an expression quantitative trait locus or eQTL) of several genes in the region (best P = 6.2 × 10 −7 for CTSK using the eQTL browser (http:// eqtl.uchicago.edu/). Perhaps the strongest candidate gene in the region is SETDB1; a recent study in zebrafish has shown a role for variation 1 1 1 6 VOLUME 43 | NUMBER 11 | NOVEMBER 2011 Nature GeNetics l e t t e r s in this gene in melanoma development 12 . Further study will be required to determine which gene or genes at this locus mediate melanoma risk.
In contrast to the 149-Mb region, the associated region at 224 Mb spans only 70 kb and encompasses a single gene in its entirety (45 kb), poly(ADP-ribose) polymerase 1 (PARP1). The peak imputed SNP is rs2695238 (P = 3.8 × 10 −7 in the Australian case-control sample, genome build 36, position 224,671,142) and lies ~9 kb upstream of the TSS of PARP1, with several highly correlated SNPs lying within PARP1. PARP1 encodes a chromatin-associated enzyme that modifies various nuclear proteins by poly(ADP)-ribosylation. The PARP1 protein has a key role in multiple cellular processes, such as differentiation, proliferation and tumor transformation, and has important functions in the repair of single-strand DNA breaks. Of note, a recent candidate gene study 13 reported a nominally significant association between the intronic PARP1 rs3219125 SNP and melanoma in a set of 585 individuals with melanoma and 585 control subjects (OR 1.89, 95% CI 1.34-2.68), with stronger effect seen in subjects with melanoma of the head and neck. The rs3219090 and rs3219125 SNPs were not highly correlated in the 1000 Genomes CEU samples (r 2 = 0.042). The rs3219125 SNP was not genotyped in our Australian discovery cohort but was well imputed (imputation r 2 = 0.70) and showed marginal evidence of association (P = 0.053). Although no strongly associated imputed or genotyped SNPs within the PARP1 locus alter the protein-coding sequence of the gene, two SNPs directly adjacent to each other and located within a nuclear factor 1 (NF1) transcription factor binding site were strongly associated (rs3754376, imputed P = 7.39 × 10 −7 , OR = 1.22; rs3754375, imputed P = 3.0 × 10 −3 , OR = 1.16). Both SNPs are in complete LD with each other and rs2695238 (pairwise D = 1 for all three pairs, pairwise r 2 in the range 0.39-0.83). Further study will be required to establish this as a melanoma risk locus and to assess whether these or other variants within this region directly mediate melanoma risk.
In our Australian discovery cohort, there remains an excess of positive results in the quantile-quantile plot after the removal of SNPs located within previously identified melanoma susceptibility regions (Supplementary Fig. 1) . A small proportion of this excess was explained by the two new chromosome 1 regions described here. Work examining the distribution of effect sizes obtained from GWAS suggests that, for a wide range of traits, there are many more loci that will be found by conducting GWAS on larger samples 14 . Our data are consistent with there being further common SNPs influencing melanoma risk, and we expect that further studies of additional individuals with melanoma will allow us to identify and characterize more loci.
In summary, our GWAS of melanoma identified one new melanoma susceptibility locus on chromosome 1 and replicated findings from 
